Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...
A U.S. federal judge rejected Novartis' efforts to block the launch of a generic version of Entresto, its blockbuster cardiovascular disease drug, per a FirstWord PHARMA report. The report noted that ...
The Federal Circuit recently reversed a District of Delaware decision that invalidated claims of Novartis’s Orange Book listed patent, U.S. Patent No. 8,101,659 (the “’659 patent”), for its ...
A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday. The U.S. Court of Appeals ...
The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...
After more than six years of high-stakes litigation in multiple courts and regulatory fights at the Food and Drug Administration (FDA), generic versions of Novartis Pharmaceuticals Corp.
FRANKFURT (Reuters) -Swiss drugmaker Novartis met third-quarter profit forecasts on Tuesday, as fast growth of newer drugs offset a sharp slowdown in blockbuster heart drug Entresto as it comes under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results